Headlines

Decision Support and Shared Decision Making Help Patients Choose Plan for Low-Risk Prostate Cancer

Decision Support and Shared Decision Making Help Patients Choose Plan for Low-Risk Prostate Cancer

Using an online decision-support tool led to most men with low-risk prostate cancer choosing active surveillance with less conflict about their decision.

Comprehensive Mental Health Screening Recommended for Some Childhood Cancer Survivors

Comprehensive Mental Health Screening Recommended for Some Childhood Cancer Survivors

Although most adolescent survivors of childhood cancer have no reported psychological symptoms, those who do often have multiple symptoms and distinct symptom profiles.

Advanced Cancer Patients Often Unaware That They Are More Optimistic About Their Prognosis Than Their Oncologists

Advanced Cancer Patients Often Unaware That They Are More Optimistic About Their Prognosis Than Their Oncologists

Most patients with advanced cancer report far more optimistic expectations for survival prognosis than their oncologists because patients misunderstand their oncologists' clinical judgment.

Transforming the Care of Patients With Thyroid Cancer

Transforming the Care of Patients With Thyroid Cancer

There were no effective therapeutic options for advanced thyroid cancer until 5 years ago.

VP Biden Talks About the Role of CancerLinQ at ASCO 2016

VP Biden Talks About the Role of CancerLinQ at ASCO 2016

At the 2016 ASCO meeting, Vice President Joe Biden spoke about his vision for comprehensive data-sharing as part of the Cancer MoonShot initiative.

Survey Highlights Barriers to Global Data Sharing

Survey Highlights Barriers to Global Data Sharing

Funding, informatics system, clinical data capture, and European data protection legislation were considered the greatest barriers to effective data sharing.

Immunotherapy Combination Is Effective in Colorectal Cancer

Cbimetinib and atezolizumab was well tolerated and demonstrated encouraging clinical activity in microsatellite stable colorectal cancer (CRC).

Monoclonal Antibody Shows Promise in Aggressive R/R Adult T-cell Leukemia/Lymphoma

Monoclonal Antibody Shows Promise in Aggressive R/R Adult T-cell Leukemia/Lymphoma

Mogamulizumab induced an encouraging response rate in patients with relapsed/refractory adult T-cell leukemia/lymphoma.

Double Autologous HCT Improves Outcomes in High-risk Pediatric Neuroblastoma

Adding a second autologous hematopoietic cell transplantation (HCT) to standard therapy improves outcomes for pediatric patients with high-risk neuroblastoma.

Web Application Improves Follow-up in Patients With Advanced Lung Cancer

Web Application Improves Follow-up in Patients With Advanced Lung Cancer

A Web application called Moovcare that guides follow-up improved survival for patients with advanced lung cancer after receiving initial therapy.

Conference Coverage

Second-Line Regorafenib Improves Overall Survival in Refractory Liver Cancer

The multikinase inhibitor regorafenib significantly improved overall survival rates compared to placebo in patients with hepatocellular carcinoma, according to data from the phase 3 RESORCE trial.

CT-Based Technique for Body Mass Measurements of Patients With Cancer Improves Disease Staging, Therapy Monitoring

A new method of measuring lean body mass accounts for changes in body composition, enabling improved disease staging and monitoring of therapy.

Overall Survival and Progression-Free Survival Are Improved With Ibrutinib for del17p CLL

Ibrutinib treatment for chronic lymphocytic leukemia with the deletion of chromosome 17p (del17p CLL) increases the percentage of patients alive at 30 months over other therapies for del17p CLL.

Premedication With Antiemetic Improves Length of Stay and Readmissions for a Liver Cancer Procedure

Including an antiemetic in the preprocedure medications for patients with liver cancer undergoing drug eluting bead chemoembolization (DEB TACE) can shorten hospital stays and reduce the chance for readmission due to complications.

Imaging Technique Is Predictive of Immunotherapy Response in Non-Small Cell Lung Cancer

Results from phase II trial on the use of FDG-PET to evaluate the efficacy of an immunotherapy drug in the treatment of NSCLC.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs